Media Releases

U of T spinoff Interface Biologics announces financing

January 13, 2015

TORONTO, ON — Inter­face Bio­log­ics Inc. (IBI), an inno­v­a­tive devel­op­er of bio­med­ical-poly­mer tech­nolo­gies which improve the safe­ty and effec­tive­ness of med­ical devices, is pleased to announce the com­ple­tion of a Series B financ­ing round led by DSM Ven­tur­ing and exist­ing investor, BDC Cap­i­tal. “Inter­face Bio­log­ics is a great strate­gic and a finan­cial invest­ment for DSM” remarked Pieter Wolters, Man­ag­ing Direc­tor of DSM Ven­tur­ing, the cor­po­rate ven­tur­ing arm of Roy­al DSM, a €10 bil­lion glob­al sci­ence-based com­pa­ny active in health, nutri­tion and mate­ri­als. “The fit with DSM’s activ­i­ties in Bio­med­ical offers sig­nif­i­cant oppor­tu­ni­ties to cre­ate incre­men­tal val­ue.”

“BDC Cap­i­tal has been an ear­ly and active investor in Inter­face Bio­log­ics since 2004”, stat­ed Dion Mad­sen, Senior Man­ag­ing Part­ner in the Health­care Ven­ture Fund at BDC. “We believe the Com­pa­ny is at the right stage to cap­i­tal­ize on the oppor­tu­ni­ty to work with a major strate­gic investor and accel­er­ate the com­mer­cial­iza­tion of its poly­mer tech­nolo­gies and the prod­ucts that they enable.”

“We’re very pleased to have com­plet­ed this Series B financ­ing”, com­ment­ed Tom Reeves, Pres­i­dent & CEO of Inter­face Bio­log­ics. “Hav­ing a strate­gic investor like DSM in com­bi­na­tion with BDC under­scores both IBI’s suc­cess to date and the con­fi­dence that our investors have in our future. We look for­ward to work­ing with DSM as we con­tin­ue the com­mer­cial devel­op­ment of our sur­face mod­i­fy­ing macro­mol­e­cules and our drug deliv­ery poly­mer tech­nol­o­gy plat­forms.”

About Inter­face Bio­log­ics, Inc.
Inter­face Bio­log­ics is a com­mer­cial stage pri­vate­ly held com­pa­ny that devel­ops trans­for­ma­tive bio­med­ical poly­mer tech­nol­o­gy to improve the safe­ty and effec­tive­ness of med­ical devices. IBI’s pri­ma­ry  tech­nol­o­gy focus areas are sur­face mod­i­fy­ing macro-mol­e­cules and poly­mer enabled com­bi­na­tion drug deliv­ery devices. IBI, a Uni­ver­si­ty of Toron­to spin­off, is locat­ed at the MaRS Cen­tre in Toron­to, Cana­da. For more infor­ma­tion about Inter­face Bio­log­ics, please vis­it

About DSM — Bright Sci­ence. Brighter Liv­ing™
Roy­al DSM is a glob­al sci­ence-based com­pa­ny active in health, nutri­tion and mate­ri­als. By con­nect­ing its unique com­pe­tences in Life Sci­ences and Mate­ri­als Sci­ences DSM is dri­ving eco­nom­ic pros­per­i­ty, envi­ron­men­tal progress and social advances to cre­ate sus­tain­able val­ue for all stake­hold­ers simul­ta­ne­ous­ly. DSM deliv­ers inno­v­a­tive solu­tions that nour­ish, pro­tect and improve per­for­mance in glob­al mar­kets such as food and dietary sup­ple­ments, per­son­al care, feed, med­ical devices, auto­mo­tive, paints, elec­tri­cal and elec­tron­ics, life pro­tec­tion, alter­na­tive ener­gy and bio-based mate­ri­als. DSM’s 24,500 employ­ees deliv­er annu­al net sales of around €10 bil­lion. The com­pa­ny is list­ed on NYSE Euronext. More infor­ma­tion can be found at

About DSM Ven­tur­ing
DSM Ven­tur­ing is an active investor in DSM’s strate­gic growth fields includ­ing Human Nutri­tion, Bio­med­ical and Solar. DSM Ven­tur­ing’s mis­sion is to explore and take posi­tions in emerg­ing com­pa­nies in these strate­gic growth fields in order to cre­ate options for DSM and cre­ate val­ue. For more infor­ma­tion about DSM Ven­tur­ing see

About BDC Cap­i­tal Health­care Ven­ture Fund
BDC Capital’s Health­care Ven­ture Fund invests in trans­for­ma­tive Cana­di­an com­pa­nies that will dra­mat­i­cal­ly increase health­care pro­duc­tiv­i­ty by reduc­ing health­care costs while improv­ing patient health. The expe­ri­enced team man­ages $270 mil­lion in cap­i­tal across two dif­fer­ent funds and invests in drugs, devices, diag­nos­tics and dig­i­tal health sec­tors. For more infor­ma­tion please vis­it


For more infor­ma­tion, con­tact:
Julie Fother­ing­ham
Part­ner, Hage­man Com­mu­ni­ca­tions
Tel: 416–951-7988